Venous thromboembolism in multiple myeloma: Increasing evidence in support of direct oral anticoagulants.
Dawn SwanClaire ComerfordJ QuinnPublished in: British journal of haematology (2023)
Venous thromboembolism (VTE) continues to cause significant morbidity and excess mortality in patients with multiple myeloma. The report by Costa and colleagues demonstrates superiority of direct oral anticoagulants over aspirin in terms of VTE prevention, without increased bleeding complications seen. Commentary on: Costa et al. Direct oral anticoagulants versus aspirin for primary thromboprophylaxis in patients with multiple myeloma undergoing outpatient therapy: A systematic review and updated meta-analysis. Br J Haematol 2023 (Online ahead of print). doi: 10.1111/bjh.19017.
Keyphrases
- venous thromboembolism
- direct oral anticoagulants
- multiple myeloma
- cardiovascular events
- systematic review
- low dose
- risk factors
- antiplatelet therapy
- atrial fibrillation
- meta analyses
- health information
- social media
- randomized controlled trial
- cardiovascular disease
- healthcare
- stem cells
- acute coronary syndrome
- bone marrow
- anti inflammatory drugs
- smoking cessation